Please login to the form below

Not currently logged in
Email:
Password:

Lilly forms hypoglycaemia drug pact

Eli Lilly has acquired worldwide commercialisation rights to a developmental hypoglycaemia therapy from Marcadia Biotech

Eli Lilly has acquired worldwide commercialisation rights to a glucagon analogue under development for severe hypoglycaemia in people with diabetes from Marcadia Biotech. Marcadia is an Indiana-based company founded five years ago to focus on developing drugs for diabetes and obesity using proprietary peptide chemistry.

The companies hope that the hypoglycaemia therapy, which is currently in preclinical development, will provide an alternative to currently marketed glucagon products, which need to be refrigerated and also must be reconstituted from a powder before they can be injected. Lilly and Marcadia aim to develop this new product as a premixed solution in a convenient single-use auto-injection "pen" device that can be stored at room temperature.

The agreement between the two companies covers the glucagon analogue MAR531 and also a stable of related back-up compounds. The deal calls for Marcadia to continue to oversee development of the product through US approval, but gives Lilly responsibility for regulatory approval in countries outside the US and for commercialisation worldwide.

MAR531 and the related compounds were discovered through Marcadia's sponsored research agreement with Indiana University, Bloomington. Financial terms of the deal with Lilly were not disclosed.

Lilly is already a leader in the diabetes space, with a portfolio that includes the type II diabetes drug Byetta (exenatide).

29th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics